The Voice of Aviles. Although the future of medicine depends on the development of new drugs for the percentage of patients who do not respond to the treatments currently offered, researchers also have to ensure the profitability of the system. Dr. Emilio Martín Mola, former head of the Rheumatology Service at Hospital de La Paz in Madrid, spoke about the appearance of biosimilar drugs, biological agents developed after the originals lost their patent and that share practically identical structures. "In terms of efficacy and safety they are also pretty much the same," he added.

READ MORE